LIN-28B/Let-7/MYCN轴在神经母细胞瘤中的研究进展

Research Progress of LIN-28B/Let-7/MYCN Axis in Neuroblastoma

神经母细胞瘤(NB)是儿童时期最常见的颅外实体肿瘤,高危患者临床进展迅速,治疗反应差,尤其晚期高危患儿对化疗及放疗不敏感,5年生存率非常低,严重影响儿童健康。MYCN癌基因、Let-7家族以及RNA结合蛋白(LIN-28B)在多种恶性肿瘤的发生发展中具有重要生物学功能,而且能够相互作用形成复杂的信号通路,在恶性肿瘤中所起的作用正日益受到重视。现有治疗对NB总体生存率的改善并不理想,MYCN癌基因、Let-7家族、LIN-28B以及LIN-28B/Let-7/MYCN轴可能在NB的发病机制中有重要作用,如果能够进一步明确NB的发病机制,或许能够为NB治疗提供新思路。

Neuroblastoma （NB） is the most common extracranial solid tumor in childhood. High-risk patients have rapid clinical progress and poor response to treatment. In particular, children with high risk at advanced stage are not sensi- tive to chemotherapy and radiotherapy. The 5-year survival rate is very low which seriously threatens the health of children. MYCN oncogene, Let-7 family and RNA-binding protein（LIN-28B） have important biological functions in the development and progression of various malignant tumors, and can interact to form complex signaling pathways, and its role in malignant tumors is getting more attention. Current treatment is not ideal for overall improvement in NB survival, since MYCN onco- gene,Let-7 family,LIN-28B and LIN-28B/Let-7/MYCN axis may play important roles in the pathogenesis of NB, further clarification of the pathogenesis of NB, may be able to provide new ideas for the treatment.